# Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

> **NCT02665065** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Actinium Pharmaceuticals** · enrollment: 153 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Leukemia, Acute Myeloid
- Myeloid Leukemia, Acute
- Leukemia, Myeloid, Acute
- Acute Myelogenous Leukemia
- Leukemia, Acute Myelogenous
- Myelogenous Leukemia, Acute
- AML
- Bone Marrow Transplant

## Interventions

- **DRUG:** Iomab-B
- **DRUG:** Conventional Care
- **PROCEDURE:** HCT

## Key facts

- **NCT ID:** NCT02665065
- **Lead sponsor:** Actinium Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-06
- **Primary completion:** 2022-06
- **Final completion:** 2026-12
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02665065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02665065, "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02665065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*